Abstract
Introduction
Datamonitor expects antidiabetic therapies to emerge as the biggest revenue
earner in the cardiovascular and metabolic markets by 2017. A large and
diverse development pipeline will provide a number of new blockbuster drugs
but the heavy genericization of the hypertension and dyslipidemia primary care
markets will lead to the overall market only growing by 0.9% in the seven
major markets.
Key reasons to purchase this research
- A detailed clinical and commercial assessment of all key cardiovascular
and metabolic therapy areas.
- An analysis of the portfolios of top 10 leading cardiovascular and
metabolic companies.
- Sales based sales forecasts for all key cardiovascular and metabolic
active agents in the seven major markets to 2017.
Table of Contents
OVERVIEW
- This product contains forecasts for the cardiovascular and metabolic
therapies across the seven major markets from 2008 to 2017. It has been
designed for delivery in an excel data pack format, but for more detail about
this disease area please see the accompanying Commercial Insight: DMHC2420
word document and PowerPoint executive presentation.
- The associated report can be found under Latest research in the
Knowledge centre, through the search function or by contacting your sales
representative.
- Please select the data pack option from the download menu at the side of
the page to access the model.
- Scope of the analysis
- Datamonitor insight into the cardiovascular market
- Forecasting Methodology
- The forecasting model:
- General event information:
- Event selection and quantification:
- Event parameters:
| 
